Teva Pharma Boosts FY23 Revenue Outlook - Update

RTTNews | vor 659 Tagen
Stocktwits
Teva Pharma Boosts FY23 Revenue Outlook - Update

(RTTNews) - While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.

For fiscal 2023, the company still projects adjusted earnings in a range of $2.25 to $2.55 per share, but now expects revenues between $15.1 billion and $15.5 billion, up from the prior forecast range between $15.0 billion and $15.4 billion.

On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $2.28 per share on revenues of $15.14 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tags: TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | vor 512 Tagen
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews | vor 650 Tagen
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | vor 757 Tagen
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | vor 841 Tagen
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | vor 850 Tagen
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.
RTTNews | vor 1154 Tagen
Japan Data On Tap For Friday

Japan Data On Tap For Friday

Japan is scheduled to release a batch of data on Friday, headlining a busy day for Asia-Pacific economic activity. On tap are July figures for unemployment, industrial production, retail sales, housing starts and construction orders, as well as August data for household confidence and Tokyo inflation.
RTTNews | vor 29 Minuten
Tools
Wirtschaftskalender
Handelszeiten
Zinssätze
Feiertagskalender
Forex-Markt
Forex-Volatilität
Forex-Korrelation
Forex-Nachrichten
Forex-Analyse
COT-Daten
Liquidität
Forex-Rechner
Forex Heatmap
Konjunkturindikatoren
Community
Community
Systeme
Beliebteste Systeme
Strategien
Wettbewerbe
Forex-Charts
Forex-Sentiment
Prognoseindikator
Bewertungen
Broker
Proprietäre Handelsfirmen
VPS-Dienste
Signalanbieter
EA Programmierdienstleistungen
Affiliate-Programme
PAMM - Broker-Dienstleistungen
Rabattprogramm-Dienstleistungen
Handelsplattformen
Expertenberater
Krypto-Börsen
Trading kurse
Broker
Forex-Spreads
Forex-Broker-Kotierungen
Forex-Broker-Swaps
Volumen des Forex-Brokers
Forex-Broker-Aktionen
Pressemitteilung
Plattform
Widgets
Funktionen
API
RSS
Stock Portfolio
Affiliate Software
Erweiterte Charts
Betreuung
FAQ
Hilfe
Kontaktieren Sie uns
Fehler melden!
Über uns
Blog
© 2025 Myfxbook Ltd. Alle Rechte vorbehalten.
WARNUNG VOR HOHEM RISIKO: Der Devisenhandel birgt ein hohes Risiko, das möglicherweise nicht für alle Anleger geeignet ist. Der Einsatz von Leverage schafft zusätzliches Risiko und Verlustgefahr. Bevor Sie sich für den Devisenhandel entscheiden, sollten Sie Ihre Anlageziele, Ihr Erfahrungsniveau und Ihre Risikotoleranz sorgfältig prüfen. Sie könnten Ihre ursprüngliche Investition teilweise oder ganz verlieren. Investieren Sie kein Geld, das Sie sich nicht leisten können, zu verlieren. Informieren Sie sich über die mit dem Devisenhandel verbundenen Risiken und lassen Sie sich von einem unabhängigen Finanz- oder Steuerberater beraten, wenn Sie Fragen haben. Alle Daten und Informationen werden ausschließlich zu Informationszwecken bereitgestellt und sind nicht für Handelszwecke oder Beratung gedacht. Die vergangene Performance ist kein Indikator für zukünftige Ergebnisse.